BRVE NASDAQ
Braveheart Bio, Inc.
1W: +13.8%
1M: +6.1%
YTD: +21.5%
$21.87
+0.00 (+0.00%)
Weekly Expected Move ±10.2%
$17
$19
$21
$24
$26
Credit Risk of going bust: not rated Bonds: none of note held by US funds details ▾
Not rated: no recent balance sheet.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$159.0M
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.5B
52W Range17.86-32
Volume101,220
Avg Volume499,903
Beta0.00
Dividend—
Analyst Ratings
Company Info
CEOTravis Murdoch
Employees49
SectorHealthcare
IndustryBiotechnology
IPO Date2026-08-06
Websitebraveheart.bio
One Letterman Drive, Building A, Suite A4-300
San Francisco, CA 94129
US
San Francisco, CA 94129
US
About Braveheart Bio, Inc.
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
Latest News
Braveheart Bio, Inc. (NASDAQ:BRVE) Sees Significant Increase in Short Interest
Braveheart Bio (NASDAQ:BRVE) Stock Falls 7.3% – Here’s What Happened
Braveheart Bio (NASDAQ:BRVE) Hits New 52-Week Low – Here’s What Happened
BRVE|Braveheart Bio Ord Shs|Price:21.200|Chg%:-2.170 - TradingKey
Braveheart Bio, Inc. (NASDAQ:BRVE) Receives Average Recommendation of "Moderate Buy" from Analysts - marketbeat.com
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Agarwala Vineeta | 0 | — | 2026-08-07 | |
| Chimovits Erez | C-Conversion | 9,132,420 | — | 2026-08-07 |
| Chimovits Erez | P-Purchase | 1,666,667 | $18.00 | 2026-08-07 |
| Chimovits Erez | P-Purchase | 273,333 | $18.00 | 2026-08-07 |
| Chimovits Erez | C-Conversion | 40,000,000 | — | 2026-08-07 |